Market update: Childhood cancer medicines available through UNICEF
From fragmented supply to sustainable access: strengthening demand visibility, quality-assured supply and pooled procurement.
Last updated 15 September 2026.
Background
This market update provides governments, procurement service partners, donors, suppliers, and other stakeholders with an overview of the medicines landscape for childhood cancers. It highlights market trends, access and supply challenges, and factors affecting market health, while identifying opportunities to strengthen the reliable availability of quality-assured medicines. The update also emphasizes how coordinated market-shaping efforts, including the Global Platform for Access to Childhood Cancer Medicines, can address persistent barriers, strengthen supply security, and support healthier and more sustainable markets for quality-assured cancer medicines.
Highlights
Healthier markets, not isolated transactions
Access depends on aligning supply and demand and addressing the interacting barriers that affect availability, accessibility, affordability and quality.
Market-shaping actions should benefit children regardless of geography or income and create conditions that can be sustained by governments, health systems and suppliers over time.
Early, accurate, financed and implementable forecasts are essential to aggregate demand, coordinate procurement windows and reduce uncertainty for suppliers.
Supplier engagement, appropriate quality pathways, product registration, long-term procurement arrangements and supplier-performance management must work together.
Pooled procurement is one intervention within a broader strategy that also includes industry engagement, stronger quality-assured supplier bases, registration pathways, de-risking instruments, market forecasts, product roadmaps, price benchmarks, sustainable financing and innovation.
UNICEF brings procurement, market intelligence, supplier engagement, quality assurance and supply-chain expertise to the Global Platform, complementing the roles of WHO, St. Jude and the PAHO Strategic Fund.
Why the childhood cancer medicines market needs to be shaped
Childhood cancer medicines serve comparatively small and dispersed patient populations. Demand is often fragmented, uncertain or underfunded; quality-assured supply can be fragile and concentrated; regulatory processes can delay market entry; and suppliers may have limited incentives to maintain low-volume products or invest in age-appropriate formulations. These constraints reinforce one another and can result in stock-outs, inconsistent access, high total procurement costs and avoidable quality risks.
The Global Platform’s market-shaping strategy responds by linking product-level action with system-level change. The objective is not simply to purchase medicines, but to improve the conditions under which countries can obtain affordable, quality-assured products reliably and sustainably.
Childhood cancer survival remains profoundly unequal worldwide, with more than 80 per cent of children in high‑income countries surviving their diagnosis compared to less than 30 per cent in many low‑ and middle‑income countries, a gap strongly linked to inconsistent access to quality‑assured cancer medicines.
Strategic direction
| Market priority | What needs to change | What this means for stakeholders |
|---|---|---|
| Demand visibility and predictability | Move from fragmented, ad hoc orders to earlier, accurate and financed demand signals. | Countries share forecasts and funding status early; partners align quantification and procurement timing. |
| Supplier participation and resilience | Maintain and broaden reliable sources for priority medicines and reduce avoidable supplier risk. | Suppliers receive clearer signals; procurement partners use structured dialogue, performance information and fit-for-purpose arrangements. |
| Regulatory and quality-assurance environment | Support appropriate quality pathways and more efficient product registration in LMICs. | Countries plan registration and import pathways early; manufacturers pursue relevant quality and registration routes. |
| Efficient procurement and sustainable financing | Use pooled procurement where feasible, coordinate procurement windows and connect purchasing commitments to available financing. | Governments and financing partners convert forecasts into procurement-ready, funded demand and plan transition to sustainable financing. |
| Market transparency and stewardship | Improve market intelligence, forecasts, product roadmaps and price information without undermining procurement strategy. | Partners use evidence to target interventions, monitor results and adjust actions by product and market segment. |
Demand, forecasting and procurement readiness
Demand visibility is only useful when it is credible and actionable. Forecasts should be based on treatment protocols, patient estimates, current stock, pipeline orders, product shelf life, delivery capacity, regulatory requirements and confirmed or reasonably anticipated financing. Requirements should be consolidated early enough to inform supplier production planning and procurement windows.
- Integrate childhood cancer medicine needs into national quantification and budgeting cycles.
- Distinguish indicative forecasts from funded, procurement-ready demand.
- Share product, formulation, strength, timing and delivery requirements early.
- Coordinate country readiness, registration or import requirements, and supply-chain capacity before orders are placed.
- Use joint planning and pooled procurement where feasible to reduce fragmentation and improve demand visibility.
Supply, supplier engagement and market resilience
UNICEF uses market intelligence, procurement data, supplier engagement, quality-assurance processes, long-term arrangements and supplier-performance management to translate consolidated demand into procurement action. The approach should be tailored to the market failure affecting each product; no single intervention is appropriate for every medicine.
- Broaden structured industry engagement to identify product- and supplier-specific barriers.
- Expand the base of quality-assured suppliers for priority medicines, including through relevant WHO quality-assurance pathways where applicable.
- Support early planning for product registration and reliance mechanisms led by the appropriate regulatory authorities.
- Use pooled procurement, coordinated procurement windows and multi-year arrangements where demand and financing permit.
- Assess volume guarantees or other de-risking instruments only where demand, financing, governance and implementation conditions are sufficiently robust.
- Improve market transparency through appropriate forecasts, product roadmaps and price benchmarks while protecting commercially sensitive procurement information.
UNICEF’s role within the Global Platform
UNICEF brings procurement, market intelligence and supply expertise to the Global Platform to help strengthen the availability and predictability of quality-assured childhood cancer medicines.
- Pooled procurement and procurement execution through UNICEF Supply Division for eligible countries and Procurement Services partners.
- Demand aggregation and coordination of procurement opportunities where feasible.
- Market intelligence, supplier landscape analysis and structured supplier engagement.
- Quality-assurance review and sourcing in line with UNICEF requirements.
- Long-term arrangements, supplier-performance management and procurement planning.
- Supply-chain guidance covering lead times, production planning, shelf life, logistics and cold-chain requirements where applicable.
- Collaboration with WHO, St. Jude, PAHO Strategic Fund, governments, regulators, financing partners, manufacturers and civil society under the Global Platform’s governance arrangements.
Priority areas for market strengthening
Priority areas for market strengthening
Industry engagement; expansion of quality-assured supply; accelerated registration pathways; expanded pooled procurement; carefully designed de-risking mechanisms; and global market forecasts.
Identification of R&D gaps and target product profiles for child-friendly formulations; product roadmaps and price benchmarks; and integration of childhood cancer medicines into national health benefit packages.
Facilitation of voluntary licensing and intellectual-property pooling for relevant on-patent medicines where these approaches can address access barriers.
Products available through UNICEF
UNICEF makes cancer-related medicines available through the UNICEF Supply and Service Catalogue. The portfolio includes medicines used in paediatric oncology treatment protocols and selected products relevant to wider cancer care. Product availability, quality-assurance status, lead time and procurement conditions should be confirmed for each requirement at the time of planning.
Illustrative product groups
Immunomodulators and antineoplastics
- Cytotoxic medicines (e.g., vincristine, etoposide and cytarabine)
- Targeted therapies (e.g., rituximab)
- Immunomodulators (e.g., filgrastim)
- Hormones and antihormones (e.g., prednisolone oral solution)
Other WHO Model List of Essential Medicines categories supporting cancer care
- Medicines for pain and palliative care (e.g., analgesics, including opioid analgesics where applicable and in line with national regulatory requirements)
- Anti-infective medicines and gastrointestinal medicines (e.g., antibiotics, antifungals and antiemetics used as supportive care in oncology protocols)
Note: Examples are illustrative and should be validated against current Supply and Service Catalogue listings, procurement data and the priority product analysis before publication.
UNICEF’s paediatric oncology product categories procurement status
Call to action
- Governments and Procurement Services partners: share early, product-specific forecasts; confirm financing; and align regulatory, procurement and delivery readiness.
- Donors and financing partners: support predictable financing and country transition plans that convert market gains into sustainable access.
- Manufacturers and suppliers: engage in structured dialogue, respond to consolidated demand signals, maintain reliable supply and pursue applicable quality and registration pathways.
- Global Platform partners: coordinate interventions, clarify roles, protect procurement-sensitive information and monitor whether actions improve market health and access.
- All stakeholders: treat childhood cancer medicines as an interconnected market and health-system challenge, not a series of stand-alone purchases.
For further questions or additional information:
- Order quantities, lead times and procurement planning: [email protected]
- Product specifications and technical questions: CPHHQ-ML-Medicines ([email protected])
- Procurement Services: [email protected]